Eupraxia Pharmaceuticals (EPRX) Other Non-Current Assets (2022 - 2026)
Eupraxia Pharmaceuticals' (EPRX) quarterly Other Non-Current Assets came in at $61754.0 in Q1 2026, down 23.03% year-on-year from $80230.0 in Q1 2025, and down 4.01% on a QoQ basis from $64332.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 5 years of Other Non-Current Assets data on file, last reported at $61754.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 23.03% year-over-year to $61754.0 in Q1 2026; TTM through Mar 2026 was $61754.0, a 23.03% decrease from a year earlier, with the FY2025 full-year figure at $64332.0, down 20.34% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $61754.0, down from $64332.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for EPRX reached as high as $1.1 million in Q3 2024 and fell as low as $2492.0 in Q4 2022.
- Historically, Other Non-Current Assets has averaged $241235.1 across 5 years, with a median of $77842.0 in 2025.
- On a YoY basis, Other Non-Current Assets climbed as much as 1340.14% in 2025 and fell as far as 92.61% in 2025.
- Year by year, Other Non-Current Assets stood at $2492.0 in 2022, then jumped by 177.05% to $6904.0 in 2023, then jumped by 1069.77% to $80761.0 in 2024, then declined by 20.34% to $64332.0 in 2025, then fell by 4.01% to $61754.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $61754.0 in Q1 2026, $64332.0 in Q4 2025, and $97597.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 14.48 Mn |
| 10 | Eupraxia Pharmaceuticals | 329.50 Mn | 329.50 Mn | - | 61,754.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,754.00 |
| Dec 31, 2025 | 64,332.00 |
| Sep 30, 2025 | 97,597.00 |
| Jun 30, 2025 | 77,842.00 |
| Mar 31, 2025 | 80,230.00 |
| Dec 31, 2024 | 80,761.00 |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 5,571.00 |
| Dec 31, 2023 | 6,904.00 |
| Dec 31, 2022 | 2,492.00 |